Systemic Inflammation Scores Predict the Activity of First-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

References

• Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55(9–10):1158–1160. doi:10.1080/0284186X.2016.1197419.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouchè O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMoa1011923.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Colloca G, Venturino A, Guarneri D. Analysis of response-related and time-to-event endpoints in randomized trials of gemcitabine-based treatment versus gemcitabine alone as first-line treatment of patients with advanced pancreatic cancer. Clin Colorectal Cancer. 2016;15(3):264–276. doi:10.1016/j.clcc.2015.11.006.
   PubMed Web of Science ®Google Scholar
• Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, et al. Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer. Clin Cancer Res. 2016;22(10):2565–2574. doi:10.1158/1078-0432.CCR-15-1732.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014;13(5):474–481. doi:10.1016/S1499-3872(14)60284-8.
   PubMed Web of Science ®Google Scholar
• Cheng H, Long F, Jaiswar M, Yang L, Wang C, Zhou Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis. Sci Rep. 2015;5(1):11026. doi:10.1038/srep11026.
   PubMedGoogle Scholar
• Yang J-J, Hu Z-G, Shi W-X, Deng T, He S-Q, Yuan S-G. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol. 2015;21(9):2807–2815. doi:10.3748/wjg.v21.i9.2807.
   PubMed Web of Science ®Google Scholar
• Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092–3100. doi:10.1007/s12032-012-0226-8.
   PubMed Web of Science ®Google Scholar
• Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–421. doi:10.1038/bjc.2013.332.
   PubMed Web of Science ®Google Scholar
• Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A, Khattak MA. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J. 2014;44(7):676–682. doi:10.1111/imj.12453.
   PubMed Web of Science ®Google Scholar
• Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014;3(2):406–415. doi:10.1002/cam4.204.
   PubMed Web of Science ®Google Scholar
• Szkandera J, Stotz M, Eisner F, Absenger G, Stojakovic T, Samonigg H, et al. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One. 2013;8(11):e78225. doi:10.1371/journal.pone.0078225.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe K, et al. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016;11(5):3441–3445. doi:10.3892/ol.2016.4381.
   PubMed Web of Science ®Google Scholar
• Colloca GA, Venturino A, Guarneri D. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy. Med Oncol. 2018;35(12):158. doi:10.1007/s12032-018-1219-z.
   PubMed Web of Science ®Google Scholar
• Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manage Res. 2017;9:471–479. doi:10.2147/CMAR.S145722.
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang W-J, Zhi Q, Shen M, Jiang M, Bian X, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8(51):88835–88844. doi:10.18632/oncotarget.21340.
   PubMedGoogle Scholar
• Reid D, Basturk O, Thirabanjasak D, Hruban RH, Klimstra DS, Bagci P, et al. Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol. 2011;24(12):1612–1619. doi:10.1038/modpathol.2011.113.
   PubMed Web of Science ®Google Scholar
• Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21(6):822–835. doi:10.1016/j.ccr.2012.04.025.
   PubMed Web of Science ®Google Scholar
• Turner N, Tran B, Tran PV, Sinnathamby M, Wong H-L, Jones I, et al. Primary tumor resection in patients with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival. Clin Colorectal Cancer. 2015;14(3):185–191. doi:10.1016/j.clcc.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ, Biankin AV, Chang DK. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg. 2018;105(2):e183–e191. doi:10.1002/bjs.10772.
   PubMed Web of Science ®Google Scholar
• Carus A, Gurney H, Gebski V, Harnett P, Hui R, Kefford R, et al. Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med. 2013;11:189. doi:10.1186/1479-5876-11-189.
   PubMed Web of Science ®Google Scholar